Systemic Corticosteroid Therapy for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Vietnam: Clinical Evaluation and Analysis of Serum Cytokines

Thi Huyen Tran; Pham Thi Lan; Tran Hau Khang; Vu Huy Luong

doi:10.3889/oamjms.2022.8052

Authors

Thi Huyen Tran Department of Dermatology and Venereology, Hanoi Medical University, Hanoi, Vietnam; Department of Outpatient, National Hospital of Dermatology and Venereology, Hanoi, Vietnam https://orcid.org/0000-0002-9794-5718
Pham Thi Lan Department of Dermatology and Venereology, Hanoi Medical University, Hanoi, Vietnam; Department of Outpatient, National Hospital of Dermatology and Venereology, Hanoi, Vietnam
Tran Hau Khang Department of Dermatology and Venereology, Hanoi Medical University, Hanoi, Vietnam; Department of Outpatient, National Hospital of Dermatology and Venereology, Hanoi, Vietnam
Vu Huy Luong Department of Dermatology and Venereology, Hanoi Medical University, Hanoi, Vietnam; Department of Outpatient, National Hospital of Dermatology and Venereology, Hanoi, Vietnam

DOI:

https://doi.org/10.3889/oamjms.2022.8052

Keywords:

Steven-Johnson syndrome, Toxic epidermal necrolysis, Severe cutaneous adverse drug reactions, Interferon-gamma, Systemic corticosteroid

Abstract

Abstract

BACKGROUND: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis are severe cutaneous adverse drug reactions. There are some immunological and genetic factors which are believed to be involved in the pathogenesis of SJS/TEN. The treatment of SJS/TEN is still controversial in which several studies showed variable results.

AIMS: To evaluate clinically the efficacy of systemic corticosteroid and to analyze some related cytokines in the treatment of SJS/TEN.

METHODS: This open, pilot and uncontrolled study was conducted at National Hospital of Dermatology and Venereology, in Hanoi, Vietnam, from October 2017 to September 2019. Methylprednisolone was indicated from the first day of hospitalization with the dose of 0.5-2.5 mg/kg/day (calculated according to prednisolone dose) once daily. It was continued until the patients got re-epithelialization. The efficacy of methylprednisolone was evaluated by observing clinically and analyzing related cytokines before and after the treatment.

RESULTS: The mean time of re-epithelialization was 15.9 days, of hospitalization was 15.9 days (range 5-30 days). There was no in-hospital mortality in this study. The most common complication was transient glycaemia (40.6%), there was no patient with sepsis. At the day of hospitalization, serum concentrations of TNF-α, IFN-γ, IL-2, IL-5, IL-13 and IL-10 were significantly higher than those at the day of re-epithelialization (p<0.05). Serum levels of IL-4, did not have significant differences between two time points (p>0.05).

CONCLUSION: The systemic corticosteroid is a good choice in the treatment of SJS/TEN. It can reduce serum levels of some cytokines that help SJS/TEN patients with avoiding mortality.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92-6. PMid:8420497 DOI: https://doi.org/10.1001/archderm.129.1.92

Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69(2):173. e1-13; quiz 185-6. https://doi.org/10.1016/j.jaad.2013.05.003 PMid:23866878 DOI: https://doi.org/10.1016/j.jaad.2013.05.003

Su SC, Mockenhaupt M, Wolkenstein P, Dunant A, Le Gouvello S, Chen CB, et al. Interleukin-15 is associated with severity and mortality in stevens-johnson syndrome/toxic epidermal necrolysis. J Invest Dermatol. 2017;137(5):1065-73. https://doi.org/10.1016/j.jid.2016.11.034 PMid:28011147 DOI: https://doi.org/10.1016/j.jid.2016.11.034

Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet Lond Engl. 1998;352(9140):1586-9. https://doi.org/10.1016/S0140-6736(98)02197-7 PMid:9843104 DOI: https://doi.org/10.1016/S0140-6736(98)02197-7

Creamer D, Walsh SA, Dziewulski P, Exton LS, Lee HY, Dart JK, et al. U.K. guidelines for the management of Stevens- Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016;174(6):1194-227. https://doi.org/10.1111/bjd.14530 PMid:27317286 DOI: https://doi.org/10.1016/j.bjps.2016.01.034

Revuz J, Penso D, Roujeau JC, Guillaume JC, Payne CR, Wechsler J, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol. 1987;123(9):1160-5. https://doi.org/10.1001/archderm.123.9.1160 PMid:3632000 DOI: https://doi.org/10.1001/archderm.123.9.1160

Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: Comparison with case-control analysis. Clin Pharmacol Ther. 2010;88(1):60-8. https://doi.org/10.1038/clpt.2009.252 PMid:20375998 DOI: https://doi.org/10.1038/clpt.2009.252

Chung WH, Wang CW, Dao RL. Severe cutaneous adverse drug reactions. J Dermatol. 2016;43(7):758-66. https://doi.org/10.1111/1346-8138.13430 PMid:27154258 DOI: https://doi.org/10.1111/1346-8138.13430

Yang L, Shou YH, Li F, Zhu XH, Yang YS, Xu JH. Retrospective study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China. Burns J Int Soc Burn Inj. 2020;46:959-69. https://doi.org/10.1016/j.burns.2019.10.008 PMid:31898979 DOI: https://doi.org/10.1016/j.burns.2019.10.008

Nassif A, Bensussan A, Dorothée G, Mami-Chouaib F, Bachot N, Bagot M, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol. 2002;118(4):728-33. https://doi.org/10.1046/j.1523-1747.2002.01622.x PMid:11918724 DOI: https://doi.org/10.1046/j.1523-1747.2002.01622.x

Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P, et al. Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol. 2004;114(5):1209-15. https://doi.org/10.1016/j.jaci.2004.07.047 PMid:15536433 DOI: https://doi.org/10.1016/j.jaci.2004.07.047

Fricke-Galindo I, LLerena A, López-López M. An update on HLA alleles associated with adverse drug reactions. Drug Metab Pers Ther. 2017;32(2):73-87. https://doi.org/10.1515/dmpt-2016-0025 PMid:28315856 DOI: https://doi.org/10.1515/dmpt-2016-0025

Chung WH, Chang WC, Lee YS, Wu YY, Yang CH, Ho HC, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA. 2014;312(5):525-34. https://doi.org/10.1001/jama.2014.7859 PMid:25096692 DOI: https://doi.org/10.1001/jama.2014.14148

Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007;48(5):1015-8. https://doi.org/10.1111/j.1528-1167.2007.01022.x PMid:17509004 DOI: https://doi.org/10.1111/j.1528-1167.2007.01022.x

Nguyen DV, Chu HC, Nguyen DV, Phan MH, Craig T, Baumgart K, et al. HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese. Asia Pac Allergy. 2015;5(2):68-77. https://doi.org/10.5415/apallergy.2015.5.2.68 PMid:25938071 DOI: https://doi.org/10.5415/apallergy.2015.5.2.68

Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134-9. https://doi.org/10.1073/pnas.0409500102 PMid:15743917 DOI: https://doi.org/10.1073/pnas.0409500102

Mounzer K, Hsu R, Fusco JS, Brunet L, Henegar CE, Vannappagari V, et al. HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: A cohort study. AIDS Res Ther. 2019;16(1):1. https://doi.org/10.1186/s12981-019-0217-3 PMid:30651100 DOI: https://doi.org/10.1186/s12981-019-0217-3

Saito N, Qiao H, Yanagi T, Shinkuma S, Nishimura K, Suto A, et al. An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions. Sci Transl Med. 2014;6(245):245ra95. https://doi.org/10.1126/scitranslmed.3008227 PMid:25031270 DOI: https://doi.org/10.1126/scitranslmed.3008227

Chung WH, Hung SI. Genetic markers and danger signals in Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergol Int. 2010;59(4):325-32. https://doi.org/10.2332/allergolint.10-RAI-0261 PMid:20962567 DOI: https://doi.org/10.2332/allergolint.10-RAI-0261

Viard-Leveugle I, Gaide O, Jankovic D, Feldmeyer L, Kerl K, Pickard C, et al. TNF-α and IFN-γ are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Invest Dermatol. 2013;133(2):489-98. https://doi.org/10.1038/jid.2012.330 PMid:22992806 DOI: https://doi.org/10.1038/jid.2012.330

Xu X, Fu XY, Plate J, Chong AS. IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: Requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res. 1998;58(13):2832-7. PMid:9661898

Posadas SJ, Padial A, Torres MJ, Mayorga C, Leyva L, Sanchez E, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol. 2002;109(1):155-61. https://doi.org/10.1067/mai.2002.120563 PMid:11799383 DOI: https://doi.org/10.1067/mai.2002.120563

Abe R, Yoshioka N, Murata J, Fujita Y, Shimizu H. Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. Ann Intern Med. 2009;151(7):514-5. https://doi.org/10.7326/0003-4819-151-7-200910060-00016 PMid:19805776 DOI: https://doi.org/10.7326/0003-4819-151-7-200910060-00016

Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol. 2008;58(1):33-40. https://doi.org/10.1016/j.jaad.2007.08.039 PMid:17919775 DOI: https://doi.org/10.1016/j.jaad.2007.08.039

Conner CD, McKenzie E, Owen CE, Callen JP. The use of cyclosporine for Stevens-Johnson syndrome-toxic epidermal necrolysis spectrum at the University of Louisville: A case series and literature review. Dermatol Online J. 2018;24(1):qt6d56n4j8. PMid:29469760 DOI: https://doi.org/10.5070/D3241037925

Valeyrie-Allanore L, Wolkenstein P, Brochard L, Ortonne N, Maître B, Revuz J, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010;163(4):847-53. https://doi.org/10.1111/j.1365-2133.2010.09863.x PMid:20500799 DOI: https://doi.org/10.1111/j.1365-2133.2010.09863.x

Lee HY, Lim YL, Thirumoorthy T, Pang SM. The role of intravenous immunoglobulin in toxic epidermal necrolysis: A retrospective analysis of 64 patients managed in a specialized centre. Br J Dermatol. 2013;169(6):1304-9. https://doi.org/10.1111/bjd.12607 PMid:24007192 DOI: https://doi.org/10.1111/bjd.12607

Paradisi A, Abeni D, Bergamo F, Ricci F, Didona D, Didona B. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol. 2014;71(2):278-83. https://doi.org/10.1016/j.jaad.2014.04.044 PMid:24928706 DOI: https://doi.org/10.1016/j.jaad.2014.04.044

Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol. 2003;139(1):39-43. https://doi.org/10.1001/archderm.139.1.39 PMid:12533162 DOI: https://doi.org/10.1001/archderm.139.1.39

Nesbitt LT. Minimizing complications from systemic glucocorticosteroid use. Dermatol Clin. 1995;13(4):925-39. PMid:8785896 DOI: https://doi.org/10.1016/S0733-8635(18)30055-X

Hirahara K, Kano Y, Sato Y, Horie C, Okazaki A, Ishida T, et al. Methylprednisolone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis: Clinical evaluation and analysis of biomarkers. J Am Acad Dermatol. 2013;69(3):496-8. https://doi.org/10.1016/j.jaad.2013.04.007 PMid:23957982 DOI: https://doi.org/10.1016/j.jaad.2013.04.007

Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2007;87(2):144-8. https://doi.org/10.2340/00015555-0214 PMid:17340021 DOI: https://doi.org/10.2340/00015555-0214

Caproni M, Torchia D, Schincaglia E, Volpi W, Frezzolini A, Schena D, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol. 2006;155(4):722-8. https://doi.org/10.1111/j.1365-2133.2006.07398.x PMid:16965421 DOI: https://doi.org/10.1111/j.1365-2133.2006.07398.x

Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis Int J Program Cell Death. 2003;8(3):237-49. DOI: https://doi.org/10.1023/A:1023668705040

Tsujimoto M, Yip YK, Vilcek J. Interferon-gamma enhances expression of cellular receptors for tumor necrosis factor. J Immunol Baltim Md 1950. 1986;136(7):2441-4. PMid:3005410

Tamura T, Ishihara M, Lamphier MS, Tanaka N, Oishi I, Aizawa S, et al. DNA damage-induced apoptosis and Ice gene induction in mitogenically activated T lymphocytes require IRF-1. Leukemia. 1997;11(Suppl 3):439-40. PMid:9209417

Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: An overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75(2):163-89. https://doi.org/10.1189/jlb.0603252 PMid:14525967 DOI: https://doi.org/10.1189/jlb.0603252

Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science. 1994;265(5168):106-9. https://doi.org/10.1126/science.8016643 PMid:8016643 DOI: https://doi.org/10.1126/science.8016643

Früh K, Yang Y. Antigen presentation by MHC Class I and its regulation by interferon gamma. Curr Opin Immunol. 1999;11(1):76-81. https://doi.org/10.1016/s0952-7915(99)80014-4 PMid:10047537 DOI: https://doi.org/10.1016/S0952-7915(99)80014-4